TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:51
Bicara Therapeutics Inc. ( BCAX ) https://www.bicara.com
19.12USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
BCAX
0.00%
SPY
32.66%
BCAX
0.00%
SPY
108.59%
BCAX
0.00%
SPY
302.52%
BCAX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
0.00
0.00
0.25
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-59.72
-59.81
0.00
Other Earnings and Cash Flow Stats:
Bicara Therapeutics Inc. ( BCAX ) Net Income TTM ($MM) is -59.48
Bicara Therapeutics Inc. ( BCAX ) Operating Income TTM ($MM) is -82.51
Bicara Therapeutics Inc. ( BCAX ) Owners' Earnings Annual ($MM) is 0.00
Bicara Therapeutics Inc. ( BCAX ) Current Price to Owners' Earnings ratio is 0.00
Bicara Therapeutics Inc. ( BCAX ) EBITDA TTM ($MM) is -82.51
Bicara Therapeutics Inc. ( BCAX ) EBITDA Margin is 0.00%
Capital Allocation:
Bicara Therapeutics Inc. ( BCAX ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Bicara Therapeutics Inc. ( BCAX ) has increased its debt by 0.445 million USD in the last 12 months
Capital Structure:
Bicara Therapeutics Inc. ( BCAX ) Interest-bearing Debt ($MM) as of last quarter is 0
Bicara Therapeutics Inc. ( BCAX ) Annual Working Capital Investments ($MM) are -4
Bicara Therapeutics Inc. ( BCAX ) Book Value ($MM) as of last quarter is 509
Bicara Therapeutics Inc. ( BCAX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Bicara Therapeutics Inc. ( BCAX ) has 520 million in cash on hand as of last quarter
Bicara Therapeutics Inc. ( BCAX ) has 14 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Bicara Therapeutics Inc. ( BCAX ) has 0 common shares outstanding as of last quarter
Bicara Therapeutics Inc. ( BCAX ) has 0 million USD of preferred stock value
Academic Scores:
Bicara Therapeutics Inc. ( BCAX ) Altman Z-Score is 0.11 as of last quarter
Bicara Therapeutics Inc. ( BCAX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Bicara Therapeutics Inc. ( BCAX ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Bicara Therapeutics Inc. ( BCAX ) for the amount of $ on
0.42% of Bicara Therapeutics Inc. ( BCAX ) is held by insiders, and 0.00% is held by institutions
Bicara Therapeutics Inc. ( BCAX ) went public on 2024-09-13
Other Bicara Therapeutics Inc. ( BCAX ) financial metrics:
FCF:0.00
Unlevered Free Cash Flow:0.00
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-13.72
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Bicara Therapeutics Inc. ( BCAX ) :
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.